CompaniesCancer Insight

Cancer Insight

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (15)
View all

Total Trials

15

As Lead Sponsor

4

As Collaborator

11

Total Enrollment

834

By Phase

PHASE1/PHASE2: 5PHASE2/PHASE3: 1PHASE1: 3PHASE2: 2NA: 1

By Status

RECRUITING: 5COMPLETED: 5ACTIVE_NOT_RECRUITING: 2NOT_YET_RECRUITING: 1WITHDRAWN: 1UNKNOWN: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Today
NCT03014076
NCT02297698
NCT05740449
NCT05658640
NCT05991388
NCT06782971
NCT05745714
NCT05751044
Hover over trial bars to see details

Recent Trials

NCT05745714Collaborator
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
PHASE1/PHASE2Recruiting
26 participants
Started: Oct 1, 2025 · Completed: Feb 2, 2032
NCT05751044Collaborator
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
PHASE1/PHASE2Recruiting
26 participants
Started: Oct 1, 2025 · Completed: Feb 1, 2032
NCT06782971Collaborator
Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
N/ARecruiting
25 participants
Started: Jun 6, 2025 · Completed: Mar 31, 2030
NCT05991388Collaborator
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
PHASE2/PHASE3Recruiting
210 participants
Started: May 2, 2024 · Completed: May 1, 2033
NCT06293105Collaborator
Social Responses to Stigma
N/ANot yet recruiting
200 participants
Started: May 1, 2024 · Completed: Jan 31, 2025
View all 15 trials →